CA2086679A1 - Conjugues contenant une toxine dirigee contre un recepteur - Google Patents

Conjugues contenant une toxine dirigee contre un recepteur

Info

Publication number
CA2086679A1
CA2086679A1 CA002086679A CA2086679A CA2086679A1 CA 2086679 A1 CA2086679 A1 CA 2086679A1 CA 002086679 A CA002086679 A CA 002086679A CA 2086679 A CA2086679 A CA 2086679A CA 2086679 A1 CA2086679 A1 CA 2086679A1
Authority
CA
Canada
Prior art keywords
toxin
receptor
molecule according
targeted
targeted toxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002086679A
Other languages
English (en)
Inventor
Hermanus A. M. Verheul
Ebo S. Bos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo NV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2086679A1 publication Critical patent/CA2086679A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002086679A 1990-07-05 1991-06-21 Conjugues contenant une toxine dirigee contre un recepteur Abandoned CA2086679A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP90201790 1990-07-05
EP90201790.4 1990-07-05

Publications (1)

Publication Number Publication Date
CA2086679A1 true CA2086679A1 (fr) 1992-01-06

Family

ID=8205057

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002086679A Abandoned CA2086679A1 (fr) 1990-07-05 1991-06-21 Conjugues contenant une toxine dirigee contre un recepteur

Country Status (7)

Country Link
EP (1) EP0537229A1 (fr)
JP (1) JPH05508634A (fr)
AU (1) AU657910B2 (fr)
CA (1) CA2086679A1 (fr)
IE (1) IE912167A1 (fr)
WO (1) WO1992000762A1 (fr)
ZA (1) ZA914933B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06508821A (ja) * 1991-03-07 1994-10-06 セラジュン　インク ウイルス病治療のための細胞表面受容体を標的とする分子の使用
DK0615451T3 (da) * 1992-05-26 2006-04-24 Immunex Corp Hidtil ukendt cytokin der binder til CD30
US5536642A (en) * 1993-09-09 1996-07-16 Barbera-Guillem; Emilio Diagnostic and prognostic methods for solid non-lymphoid tumors and their metastases
WO1996040260A2 (fr) * 1995-06-07 1996-12-19 Innogenetics N.V. Immunotoxines specifiques aux cellules exprimant cd80 et cd86
ES2191827T3 (es) * 1996-10-17 2003-09-16 Immunomedics Inc Conjugado de toxina no antigenica y proteina de fusion de un sistema receptor de penetracion intracelular.
US6703488B1 (en) 1998-01-15 2004-03-09 Center For Molecular Medicine And Immunology Antibody/receptor targeting moiety for enhanced delivery of armed ligand
ATE424415T1 (de) * 1998-01-15 2009-03-15 Ct Molecular Med & Immunology BISPEZIFISCHE ßTARGETING MOIETYß UMFASSEND EINEN ANTIKÖRPER GEGEN CEA (CARCINOEMBRYONIC ANTIGEN) UND DIE LIGANDEN-BINDENDE REGION DER IL13REZEPTOR ALPHA UNTEREINHEIT
MX368016B (es) * 2013-08-14 2019-09-13 Univ Rice William M Derivados de uncialamicina, métodos de sintesis y su uso como agentes antitumor.
WO2023137443A1 (fr) * 2022-01-14 2023-07-20 Regeneron Pharmaceuticals, Inc. Dérivés de verrucarine a et conjugués anticorps-médicament de ceux-ci

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002061A1 (fr) * 1985-10-03 1987-04-09 Biotechnology Research Partners, Ltd. Nouveaux systemes d'administration de medicaments a base de lipoproteines
IN165717B (fr) * 1986-08-07 1989-12-23 Battelle Memorial Institute
AU2635088A (en) * 1987-12-04 1989-06-08 Du Pont Merck Pharmaceutical Company, The Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension
DE68917138T2 (de) * 1988-05-19 1995-02-23 Beth Israel Hospital Toleranzinduktion gegenüber einem fremdantigen.
JPH03500415A (ja) * 1988-07-05 1991-01-31 アムジエン・インコーポレーテツド インターロイキン２類似体
US5149782A (en) * 1988-08-19 1992-09-22 Tanox Biosystems, Inc. Molecular conjugates containing cell membrane-blending agents

Also Published As

Publication number Publication date
IE912167A1 (en) 1992-01-15
AU657910B2 (en) 1995-03-30
JPH05508634A (ja) 1993-12-02
ZA914933B (en) 1992-04-29
WO1992000762A1 (fr) 1992-01-23
AU8060691A (en) 1992-02-04
EP0537229A1 (fr) 1993-04-21

Similar Documents

Publication Publication Date Title
US6083926A (en) Water soluble vitamin B12 receptor modulating agents and methods related thereto
AU2020200975B2 (en) New stable antibody-drug conjugate, preparation method therefor, and use thereof
EP1198254B1 (fr) Conjugue excipient-produit pharmaceutique
US6310039B1 (en) Antineoplastic conjugates of transferrin, albumin and polyethylene glycol
US4987237A (en) Derivatives of monophosphoryl lipid A
US5280113A (en) Method for producing synthetic N-linked glycoconjugates
US4625014A (en) Cell-delivery agent
US5843903A (en) Targeted cytotoxic anthracycline analogs
US4046722A (en) Immunological materials
US5840880A (en) Receptor modulating agents
US5869465A (en) Methods of receptor modulation and uses therefor
HU193737B (en) Process for preparing transferrin-indole-dihydroindole alkaloid derivatives
RU2170234C2 (ru) Модифицированные углеводами цитостатические средства
Smyth et al. Specific targeting of chlorambucil to tumors with the use of monoclonal antibodies
AU657910B2 (en) Receptor directed-toxin conjugates
HU218603B (hu) Célspecifikus antitest-szuperantigén konjugátumok és ezen készítmények előállítása
US5739287A (en) Biotinylated cobalamins
JPS60133367A (ja) リドカインおよびその類縁体のための免疫原
US5144012A (en) Cytotoxic drug conjugates
EP0476408A1 (fr) Conjugaison chimique de morpholino-anthracyclines avec des anticorps
US5798097A (en) Immunogobulin conjugates
Goerlach et al. In vitro antitumor activity of 2'-deoxy-5-fluorouridine-monoclonal antibody conjugates
CA2109636A1 (fr) Procede de preparation d'immunoconjugues
EP1015475A1 (fr) Agents de modulation des recepteurs de la vitamine b 12?
WO1997014711A9 (fr) Agents de modulation des recepteurs de la vitamine b¿12?

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead